NASDAQ:RARE Ultragenyx Pharmaceutical Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $60.57 +0.58 (+0.97%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$57.19▼$60.6950-Day Range$45.80▼$78.7252-Week Range$45.20▼$104.38Volume653,293 shsAverage Volume507,587 shsMarket Capitalization$4.24 billionP/E RatioN/ADividend YieldN/APrice Target$111.29 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Stock Forecast (MarketRank)Overall MarketRank™2.28 out of 5 starsMedical Sector294th out of 1,417 stocksPharmaceutical Preparations Industry119th out of 675 stocksAnalyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 - 3.3 Analyst's Opinion Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 8 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $111.29, Ultragenyx Pharmaceutical has a forecasted upside of 83.7% from its current price of $60.57.Amount of Analyst CoverageUltragenyx Pharmaceutical has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesUltragenyx Pharmaceutical has received 776 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUltragenyx Pharmaceutical has received 204 “underperform” votes. (Add your “underperform” vote.)Community SentimentUltragenyx Pharmaceutical has received 79.18% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote “Outperform” if you believe RARE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,321.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.49% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($7.15) to ($5.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -8.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -8.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ultragenyx Pharmaceutical (NASDAQ:RARE)Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.Read More RARE Stock News HeadlinesJune 24, 2022 | seekingalpha.comEMA panel recommends extending indication for low blood phosphate treatment CrysvitaJune 23, 2022 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Erik Harris Sells 295 Shares of StockJune 23, 2022 | americanbankingnews.comStockNews.com Downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to SellJune 16, 2022 | americanbankingnews.comComparing Ultragenyx Pharmaceutical (NASDAQ:RARE) & Ovid Therapeutics (NASDAQ:OVID)June 14, 2022 | nasdaq.comIonis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan TagJune 14, 2022 | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Upgraded by StockNews.com to "Hold"June 13, 2022 | finance.yahoo.comUltragenyx Pharmaceutical (NASDAQ:RARE) shareholders have endured a 51% loss from investing in the stock a year agoJune 1, 2022 | finance.yahoo.comUltragenyx to Present at Jefferies Global Healthcare ConferenceMay 24, 2022 | markets.businessinsider.comExpert Ratings for Ultragenyx PharmaceuticalMay 19, 2022 | finance.yahoo.comUltragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual MeetingMay 17, 2022 | seekingalpha.comUltragenyx to buy global rights to Abeona's gene therapy ABO-102 for fatal brain condition in kidsMay 17, 2022 | marketwatch.comUltragenyx Licenses Sanfilippo Program From Abeona >RARE ABEOMay 17, 2022 | finance.yahoo.comUltragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona TherapeuticsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RARE CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,119Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today6/26/2022Next Earnings (Estimated)8/01/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$111.29 High Stock Price Forecast$162.00 Low Stock Price Forecast$73.00 Forecasted Upside/Downside+83.7%Consensus RatingModerate Buy Rating Score (0-4)2.58333333333333 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($6.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-454.02 million Net Margins-141.65% Pretax Margin-141.28% Return on Equity-49.18% Return on Assets-30.20% Debt Debt-to-Equity RatioN/A Current Ratio4.23 Quick Ratio4.12 Sales & Book Value Annual Sales$351.41 million Price / Sales12.05 Cash FlowN/A Price / Cash FlowN/A Book Value$13.53 per share Price / Book4.48Miscellaneous Outstanding Shares69,930,000Free Float65,245,000Market Cap$4.24 billion OptionableOptionable Beta1.61 Ultragenyx Pharmaceutical Frequently Asked Questions Should I buy or sell Ultragenyx Pharmaceutical stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Ultragenyx Pharmaceutical stock. View analyst ratings for Ultragenyx Pharmaceutical or view top-rated stocks. What is Ultragenyx Pharmaceutical's stock price forecast for 2022? 12 equities research analysts have issued twelve-month price objectives for Ultragenyx Pharmaceutical's shares. Their RARE stock forecasts range from $73.00 to $162.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $111.29 in the next twelve months. This suggests a possible upside of 83.7% from the stock's current price. View analysts' price targets for Ultragenyx Pharmaceutical or view top-rated stocks among Wall Street analysts. How has Ultragenyx Pharmaceutical's stock price performed in 2022? Ultragenyx Pharmaceutical's stock was trading at $84.09 at the beginning of the year. Since then, RARE shares have decreased by 28.0% and is now trading at $60.57. View the best growth stocks for 2022 here. When is Ultragenyx Pharmaceutical's next earnings date? Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022. View our earnings forecast for Ultragenyx Pharmaceutical. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($2.19) earnings per share for the quarter, missing analysts' consensus estimates of ($1.76) by $0.43. The biopharmaceutical company earned $79.94 million during the quarter, compared to the consensus estimate of $84.25 million. Ultragenyx Pharmaceutical had a negative net margin of 141.65% and a negative trailing twelve-month return on equity of 49.18%. Ultragenyx Pharmaceutical's quarterly revenue was down 19.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.03) EPS. View Ultragenyx Pharmaceutical's earnings history. Who are Ultragenyx Pharmaceutical's key executives? Ultragenyx Pharmaceutical's management team includes the following people: Dr. Emil D. Kakkis M.D., Ph.D., Pres, CEO & Director (Age 62, Pay $1.28M)Ms. Mardi C. Dier, Exec. VP & CFO (Age 58, Pay $812.24k) (LinkedIn Profile)Mr. John Richard Pinion II, Chief Quality Operations Officer & Exec. VP of Translational Sciences (Age 56, Pay $743.58k) (LinkedIn Profile)Dr. Camille L. Bedrosian M.D., Chief Medical Officer & Exec. VP (Age 69, Pay $825.08k) (LinkedIn Profile)Mr. Erik Harris, Exec. VP & Chief Commercial Officer (Age 51, Pay $797.57k) (LinkedIn Profile)Mr. Theodore A. Huizenga, Sr. VP, Corp. Controller & Principal Accounting Officer (Age 51) (LinkedIn Profile)Mr. Dennis Karl Huang, Chief Technical Operations Officer & Exec. VP (Age 57) (LinkedIn Profile)Ms. Danielle Keatley, Sr. Director of Investor Relations & Corp. CommunicationsMs. Karah Herdman Parschauer J.D., Gen. Counsel & Exec. VP (Age 44) (LinkedIn Profile)Mr. Ernie W. Meyer, Chief HR Officer & Exec. VP (Age 58) What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO? 41 employees have rated Ultragenyx Pharmaceutical CEO Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among Ultragenyx Pharmaceutical's employees. Who are some of Ultragenyx Pharmaceutical's key competitors? Some companies that are related to Ultragenyx Pharmaceutical include UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Shiseido (SSDOY), Viatris (VTRS), Ono Pharmaceutical (OPHLF), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Elanco Animal Health (ELAN), Jazz Pharmaceuticals (JAZZ), Dr. Reddy's Laboratories (RDY), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Legend Biotech (LEGN), Grifols (GRFS) and Maravai LifeSciences (MRVI). View all of RARE's competitors. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM). What is Ultragenyx Pharmaceutical's stock symbol? Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE." Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.53%), Federated Hermes Inc. (5.70%), BlackRock Inc. (4.96%), Wellington Management Group LLP (4.82%), Capital International Investors (4.78%) and Clearbridge Investments LLC (4.10%). Company insiders that own Ultragenyx Pharmaceutical stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski. View institutional ownership trends for Ultragenyx Pharmaceutical. Which institutional investors are selling Ultragenyx Pharmaceutical stock? RARE stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Invesco Ltd., Bank of New York Mellon Corp, Emerald Mutual Fund Advisers Trust, Capital Group International Inc. CA , BlackRock Inc., Capital International Ltd. CA, and Citigroup Inc.. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last two years include Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg, and William Aliski. View insider buying and selling activity for Ultragenyx Pharmaceutical or view top insider-selling stocks. Which institutional investors are buying Ultragenyx Pharmaceutical stock? RARE stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, State Street Corp, Rock Springs Capital Management LP, Dimensional Fund Advisors LP, Peregrine Capital Management LLC, International Biotechnology Trust PLC, Verition Fund Management LLC, and Verition Fund Management LLC. View insider buying and selling activity for Ultragenyx Pharmaceutical or or view top insider-buying stocks. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ultragenyx Pharmaceutical's stock price today? One share of RARE stock can currently be purchased for approximately $60.57. How much money does Ultragenyx Pharmaceutical make? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $4.24 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454.02 million in net income (profit) each year or ($6.87) on an earnings per share basis. How many employees does Ultragenyx Pharmaceutical have? Ultragenyx Pharmaceutical employs 1,119 workers across the globe. How can I contact Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at [email protected], or via fax at 415-483-8810. This page (NASDAQ:RARE) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here